Enliven therapeutics reports first quarter financial results and provides a business update

Updated data from the phase 1 enable clinical trial of elvn-001 in cml to be presented at the eha 2025 congress in june eha abstract reported cumulative mmr rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving mmr by 24 weeks, and elvn-001 remains well-tolerated with 74 patients enrolled enliven to host a webcast and conference call following the oral presentation at eha on friday, june 13, at 1:30 p.m. et strong balance sheet with $ 290 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2027 boulder, colo.
ELVN Ratings Summary
ELVN Quant Ranking